This month, mental health professionals from across the country gathered in New York, New York, for a pair of conferences that addressed advances in treating mental health disorders. Below are 5 key takeaways from the meetings on new directions in the field.
This month, mental health professionals from across the country gathered in New York, New York, for a pair of conferences that addressed advances in treating mental health disorders. Below are 5 key takeaways from the meetings on new directions in mental health care.
1. Depression might be fundamentally different in men and women
At the opening plenary of the 73rd Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) meeting in New York City, Eric J. Nestler, MD, PhD, explained that depression may be fundamentally different in male and female patients.
Nestler, the Nash Family Professor of Neuroscience and director of the Friedman Brain Institute, explained that, in examining tissue from 2 brain banks, researchers have found more genetic abnormalities in the brains of males with depression than in the brains of females with the same diagnosis, and there was only a 5% to 10% concordance in gene overlap in these samples. This research, he suggested, may make a compelling case for sex-specific targeted therapies for depression.
2. A new treatment for depression shows reduced abuse potential
Not all patients have an adequate response to existing pharmacological treatments for major depressive disorder, and concerns linger about the abuse potential of some agents. At the SOBP meeting, researchers presented findings that adding an opioid receptor antagonist lowers the abuse potential of an adjunctive drug therapy for major depressive disorder.
ALKS 5461, an investigational drug therapy, combines buprenorphine with samidorphan, a µ-opioid receptor antagonist. In a study of nondependent, opioid-experienced volunteers, the incidence of euphoria-related adverse events was as low for the study drug as it was for placebo, and there was no evidence of dependence or withdrawal from the drug.
Separate research, presented at the American Psychiatric Association's (APA's) 2018 Annual Meeting, demonstrated that the drug has a durable antidepressant effect up to 52 weeks.
3. Mental health care must target primary prevention
Benjamin G. Druss, MD, of the Rollins School of Public Health at Emory University, explained during a session of the APA meeting, explained that mental healthcare, which currently focuses on preventing disability or bad outcomes once a patient already has a mental health disorder, needs to shift its focus to primary prevention work that applies to whole populations. Targets for action include social factors and how social determinants of health lead to other problems. It requires going “way upstream,” he explained, to address issues related to the environment, poverty, and adverse childhood events.
4. Telepsychiatry fills in gaps in psychiatric care in underserved areas
Also at the APA meeting, representatives of Project Extension for Community Healthcare Outcomes (ECHO), a program that delivers psychiatric care to underserved patients in the United States and Canada, explained that telepsychiatry can expand access to much needed care, particularly in rural areas.
The ECHO program uses a model in which a 2-hour clinic is held every week, and primary care physicians dial in to consult with psychiatric specialists. The clinic includes a discussion on best practices and a more detailed look at anonymized cases. Finally, the specialists provide recommendations for implementation that primary care physicians can use in practice.
5. Digital innovations demonstrate positive outcomes in treating common mental health issues
Finally, at the APA meeting, Kathryn M. Salisbury PhD, executive vice president of the Mental Health Association of New York City, explained that her organization’s platform, iHELP Sandy, which was developed and rolled out in the wake of superstorm Sandy, enrolled over 4000 individuals in digital services to treat depression, anxiety, and other mental health needs in the wake of the disaster. Through April 2016, said Salisbury, 59% of the individuals engaged in the iHELP Sandy program showed an improvement from baseline of at least 24%, and 89% of individuals who had severe impairment had improved by 44%.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
FDA Approves Vutrisiran to Mitigate Cardiomyopathy-Related Risks and Conditions
March 21st 2025In a recent decision, the FDA approved vutrisiran (amvuttra), making it the only approved therapy for adults with hereditary transthyretin-mediated amyloidosis (ATTR-CM) or wild-type cardiomyopathy.
Read More
Streamlining "Brain-to-Vein" Time, Patient Selection, Imperative for Implementing CAR T for MM
March 21st 2025Ajai Chari, MD, University of California San Francisco, explores the challenges that accompany integrating chimeric antigen receptor (CAR) T-cell therapies into multiple myeloma treatment.
Read More